NDA 21039, held by Glaxosmithkline. Amprenavir.
As of Nov 16, 2026, NDA 21039 (Agenerase), held by Glaxosmithkline, was first approved by FDA on Apr 15, 1999, with 15 approved supplements and 0 published complete response letters.
| Feb 5, 2002 | Supplement 9Efficacy (new indication or use) | Approved | |
| May 11, 2001 | Supplement 6Efficacy (new indication or use) | Approved | |
| Apr 15, 1999 | Original applicationNew dosage form | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Agenerase15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ยท solution;oral | Amprenavir | DiscontinuedReference drug |
| Nov 4, 2005 | Supplement 17Labeling | Approved | |
| Feb 12, 2004 | Supplement 16Labeling | Approved | |
| Dec 24, 2002 | Supplement 15Manufacturing | Approved | None posted |
| Oct 2, 2002 | Supplement 14Labeling | Approved | |
| Oct 2, 2002 | Supplement 13Labeling | Approved | |
| Aug 2, 2002 | Supplement 10Labeling | Approved | |
| Feb 5, 2002 | Supplement 12Labeling | Approved | |
| Feb 5, 2002 | Supplement 9Efficacy (new indication or use) | Approved | |
| May 11, 2001 | Supplement 6Efficacy (new indication or use) | Approved | |
| May 9, 2001 | Supplement 8Labeling | Approved | None posted |
| Dec 19, 2000 | Supplement 5Labeling | Approved | None posted |
| Apr 28, 2000 | Supplement 2Labeling | Approved | None posted |
| Apr 24, 2000 | Supplement 3Labeling | Approved | None posted |
| Dec 22, 1999 | Supplement 4Manufacturing | Approved | None posted |
| Sep 22, 1999 | Supplement 1Labeling | Approved | None posted |
| Apr 15, 1999 | Original applicationNew dosage form | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters